Understanding how MUC5B contributes to lung injury and fibrosis
Official title: Diversity Supplement to Mechanisms Regulating Lung Injury and Early Lung Fibrosis
Funded at University of Colorado Denver · NIH-11012571 · Data updated 2026-11-12
This study is looking at how a molecule called MUC5B makes lungs more prone to damage, which can lead to conditions like idiopathic pulmonary fibrosis (IPF), and it aims to find ways to help prevent or treat these lung issues for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | September 18, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $207,079 |
| NIH project number | 3P01HL162607-02S1 |
| Project ID | NIH-11012571 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with genetic variants related to MUC5B and those experiencing early signs of lung injury.
✕Less likely to help
Patients with established lung fibrosis or those without the genetic predisposition related to MUC5B may not benefit from this research.
What this research studies
This research investigates the role of a specific molecule called MUC5B in making the lungs vulnerable to injury and how this vulnerability can lead to conditions like idiopathic pulmonary fibrosis (IPF). The study aims to identify the mechanisms by which MUC5B affects lung cells and contributes to persistent lung damage and fibrosis. By examining the interactions between lung epithelial cells and fibroblasts, the research seeks to uncover the factors that trigger and exacerbate lung injury. Patients may benefit from insights gained into how to prevent or treat lung conditions associated with MUC5B.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating lung fibrosis in patients at risk.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic factors in lung diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Schwartz, David Albert — University of Colorado Denver
- Study coordinator: Schwartz, David Albert
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.